FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per	
response	0.5

Trust (5)

Check this box if no longer subject Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)																
Name and Address of Reporting Person – Kazarian Gregory N.				2. Issuer Name and Ticker or Trading Symbol P3 Health Partners Inc. [PIII]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X. Director 10% Owner							
(Last) (First) (Middle) C/O P3 HEALTH PARTNERS INC., 2370 CORPORATE CIRCLE, SUITE 300				3. Date of Earliest Transaction (Month/Day/Year) 12/03/2021						Officer (g	ive title below)	_	Other (specify bel	ow)		
(Street) HENDERSON,, NV 89074				4. If Amendment, Date Original Filed(Month/Day/Year) 12/07/2021						6. Individual or Joint/Group FilingCheck Applicable Line) X. Form filed by Ghe Reporting Person Form filed by More than One Reporting Person						
(City)	(Cita) (Cita) (Cita)					rities Acqu	Acquired, Disposed of, or Beneficially Owned									
		2. Transacti (Month/Day	(Year) Exection	Deemed ution Date, if	ì í		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			6. Ownership Form:	Beneficial			
				(Mon	nth/Day/Year)	Code	V	Amount	(A) or (D)	Price					Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Class V Common Stock	1)		12/03/202	11		A		706,595 (2)	A	\$ 70.66 (3)	706,595 (2	95 (2)			D	
Class V Common Stock (1)			12/03/202	21		A		471,064	A	\$ 47.11 (3)	471,064			I	By Kazarian 2020 Irrevocable Trust (5)	
Reminder: Report on a separate	e line for each class	of securities beneficial	lly owned directly or			r	espond	d unless the	form disp	lays a curr		on contained in this DMB control numbe		required to	S	EC 1474 (9-02
				Table II		Securities Acquired calls, warrants, opti				vned						
1. Title of Derivative Security (Instr. 3)	Exercise Price of (Month/Day/Year) Execution Derivative any		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction (Instr. 8)	(Instr. 8) Secur Dispo		Number of Derivative curities Acquired (A) or sposed of (D) str. 3, 4, and 5)				 Title and Amount of Underlying Securities (Instr. 3 and 4) 		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially	Ownership Form of Derivative	Beneficial Ownership
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	n Title		Amount or Number of Shares		Owned Following Reported Transaction(s) (Instr. 4)	ing Direct (D) ed or Indirect ction(s) (I)	(Instr. 4)
Common Units (3)	<u>(4)</u>	12/03/2021		A		706,595 (2)		<u>(4)</u>	<u>(4)</u>		A Common Stock	706,595	(3)	706,595 (2)	D	
Common Units (3)	<u>(4)</u>	12/03/2021		A		471,064		<u>(4)</u>	<u>(4)</u>		A Common Stock	471,064	(3)	471,064	I	By Kazarian 2020

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Kazarian Gregory N. C/O P3 HEALTH PARTNERS INC. 2370 CORPORATE CIRCLE, SUITE 300 HENDERSON,, NV 89074	Х					

Signatures

/s/ Jessica Puathasnanon, as attorney-in-fact	02/15/2022
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ${}^{\star\star} \quad \text{Intentional misstatements or omissions of facts constitute Federal Criminal Violations.} \textit{See} \ 18 \text{ U.S.C.} \ 1001 \ \text{and} \ 15 \text{ U.S.C.} \ 78 \text{ff(a)}.$
- (1) Upon the redemption of any Common Units (as defined below), a number of shares of Class V Common Stock equal to the number of Common Units that are redeemed will be cancelled by the Issuer for no consideration.
- (2) Includes 102,785 shares of Class V common stock and 102,785 Common Units of P3 Health Group, LLC being held in escrow following the business combination described below until the resolution of a dispute among the former unitholders of P3 Health Group Holdings, LLC in accordance of the holizon and the second of the second of the holizon and the second of the
- At the closing of the business combination pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), as described in the Issuer's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on October 28, 2021, as supplemented, the recipion "Common Units"), a direct subsidiary of the Issuer, as consideration for the common units of P3 Health Group Holdings, LLC. In connection with the receipt of Common Units, each recipient subscribed for an equal number of shares of Class V Common Stock of the Issuer for a purchas
- (4) The Common Units are redeemable at any time by the reporting person for, at the election of the Issuer, newly-issued Class A Common Stock of the Issuer on a one-for-one basis or a cash payment equal to the volume weighted average market price of one share of Class A Common Stock of the Issuer on consideration.
- (5) These securities are held by the Kazarian 2020 Irrevocable Trust, a trust for which the reporting person's spouse serves as trustee.

Remarks

This Form 4/A amends the Form 4 filed by the reporting person on December 7, 2021 to reflect that 471,064 shares of Class V common stock and 471,064 Common Units are held directly by a trust of which the reporting person's spouse

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.